CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)
CRISPR Therapeutics AG (CRSP) posted Change in Receivables of -$25.0 million for Q1 2025, down 200.0% sequentially from $25.0 million in Q4 2024, and up 87.5% YoY from -$13.3 million in Q1 2024.
CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025) Analysis & Trends
CRISPR Therapeutics AG has reported Change in Receivables for 10 years, with the latest figure at -$25.0 million in Q1 2025.
- Quarterly Change in Receivables rose 87.5% year-over-year to -$25.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$25.0 million (up 85.71% YoY) and the FY2025 annual result came in at -$25.0 million, up 85.71% from the prior year.
- Change in Receivables fell to -$25.0 million in Q1 2025 per CRSP's latest filing, from $25.0 million in the prior quarter.
- Over five years, Change in Receivables peaked at $200.0 million in Q4 2023 and troughed at -$200.0 million in Q1 2024.
- A 5-year average of -$11076.9 and a median of -$17000.0 in 2022 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 408263.27% in 2023, down 411664.71% in 2023.
- Over 5 years, Change in Receivables stood at $153000.0 in 2021, then tumbled by 132.03% to -$49000.0 in 2022, then soared by 408263.27% to $200.0 million in 2023, then tumbled by 87.5% to $25.0 million in 2024, then slumped by 200.0% to -$25.0 million in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$25.0 million, $25.0 million, and -$200.0 million for Q1 2025, Q4 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -25.00 Mn |
| Mar 31, 2025 | -25.00 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Mar 31, 2024 | -200.00 Mn |
| Mar 31, 2024 | -200.00 Mn |
| Dec 31, 2023 | 200.00 Mn |
| Dec 31, 2023 | 200.00 Mn |
| Sep 30, 2023 | -70.00 Mn |
| Sep 30, 2023 | -70.00 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Dec 31, 2022 | -49,000.00 |
| Dec 31, 2022 | -49,000.00 |
| Sep 30, 2022 | -17,000.00 |
| Sep 30, 2022 | -17,000.00 |
| Jun 30, 2022 | -77,000.00 |
| Jun 30, 2022 | -77,000.00 |
| Mar 31, 2022 | -162,000.00 |
| Mar 31, 2022 | -162,000.00 |